Since 2014 dulaglutide has been approved alone or in combination with other drugs for the treatment of adults with type 2 diabetes. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapies. 

IQWiG found a hint of minor added benefit for the combination with short-acting insulin with or without metformin. In contrast, an added benefit of dulaglutide versus the respective appropriate comparator therapy is not proven for the combination with long-acting insulin, for monotherapy, and for combinations with one or two oral anti-diabetics.

For more details, go to: https://www.iqwig.de/en/press/press-releases/press-releases/dulaglutide-in-type-2-diabetes-hint-of-an-added-benefit-in-combination-with-short-acting-insulin.6667.html